JPS58174313A - 動物組織の線維化抑制剤 - Google Patents

動物組織の線維化抑制剤

Info

Publication number: JPS58174313A
Authority: JP; Japan
Prior art keywords: remedy; prevention; compound; animal tissue; fibrosing
Prior art date: 1982-04-06
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

JP57057474A

Other languages

English (en)

Japanese (ja)

Other versions

JPH0139405B2 (2

Inventor

Isuke Imada

今田　伊助

Masazumi Watanabe

渡辺　正純

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Takeda Pharmaceutical Co Ltd

Original Assignee

Takeda Chemical Industries Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1982-04-06

Filing date

1982-04-06

Publication date

1983-10-13

1982-04-06 Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd

1982-04-06 Priority to JP57057474A priority Critical patent/JPS58174313A/ja

1983-03-25 Priority to US06/479,074 priority patent/US4514420A/en

1983-03-31 Priority to DE3311922A priority patent/DE3311922C2/de

1983-03-31 Priority to IT48031/83A priority patent/IT1167113B/it

1983-10-13 Publication of JPS58174313A publication Critical patent/JPS58174313A/ja

1989-08-21 Publication of JPH0139405B2 publication Critical patent/JPH0139405B2/ja

Status Granted legal-status Critical Current

Links

241001465754 Metazoa Species 0.000 title claims abstract description 8
150000001875 compounds Chemical class 0.000 claims abstract description 18
125000000217 alkyl group Chemical group 0.000 claims abstract description 4
206010016654 Fibrosis Diseases 0.000 claims description 6
230000004761 fibrosis Effects 0.000 claims description 6
239000003112 inhibitor Substances 0.000 claims description 5
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims 1
206010003210 Arteriosclerosis Diseases 0.000 abstract description 4
108010035532 Collagen Proteins 0.000 abstract description 4
102000008186 Collagen Human genes 0.000 abstract description 4
208000011775 arteriosclerosis disease Diseases 0.000 abstract description 4
206010003246 arthritis Diseases 0.000 abstract description 4
229920001436 collagen Polymers 0.000 abstract description 4
230000002265 prevention Effects 0.000 abstract description 4
102000004079 Prolyl Hydroxylases Human genes 0.000 abstract description 3
108010043005 Prolyl Hydroxylases Proteins 0.000 abstract description 3
241000124008 Mammalia Species 0.000 abstract description 2
206010039710 Scleroderma Diseases 0.000 abstract description 2
238000009825 accumulation Methods 0.000 abstract description 2
230000015572 biosynthetic process Effects 0.000 abstract description 2
231100000053 low toxicity Toxicity 0.000 abstract description 2
206010028537 myelofibrosis Diseases 0.000 abstract description 2
201000009925 nephrosclerosis Diseases 0.000 abstract description 2
-1 6-substituted-2,3-dimethoxy-5-methyl-1,4-benzoquinone Chemical class 0.000 abstract 1
108010050808 Procollagen Proteins 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
201000010260 leiomyoma Diseases 0.000 abstract 1
210000004072 lung Anatomy 0.000 abstract 1
238000000034 method Methods 0.000 description 7
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
230000002401 inhibitory effect Effects 0.000 description 6
230000036570 collagen biosynthesis Effects 0.000 description 5
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
241000700159 Rattus Species 0.000 description 3
239000002775 capsule Substances 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
239000003814 drug Substances 0.000 description 3
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
239000000203 mixture Substances 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
229940005561 1,4-benzoquinone Drugs 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 2
208000019425 cirrhosis of liver Diseases 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
238000000921 elemental analysis Methods 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000000155 melt Substances 0.000 description 2
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
239000007901 soft capsule Substances 0.000 description 2
239000002689 soil Substances 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 1
ZYBUZIVBOWJDJA-UHFFFAOYSA-N 2-(hydroxymethyl)-5,6-dimethoxy-3-methylcyclohexa-2,5-diene-1,4-dione Chemical compound COC1=C(OC)C(=O)C(CO)=C(C)C1=O ZYBUZIVBOWJDJA-UHFFFAOYSA-N 0.000 description 1
ZIWQTDIDVQRWAH-UHFFFAOYSA-N 2-hydroxy-3-oxobutanoyl chloride Chemical compound CC(=O)C(O)C(Cl)=O ZIWQTDIDVQRWAH-UHFFFAOYSA-N 0.000 description 1
235000011293 Brassica napus Nutrition 0.000 description 1
240000008100 Brassica rapa Species 0.000 description 1
235000000540 Brassica rapa subsp rapa Nutrition 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
206010058314 Dysplasia Diseases 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
235000019502 Orange oil Nutrition 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
239000002253 acid Substances 0.000 description 1
229940121369 angiogenesis inhibitor Drugs 0.000 description 1
239000004037 angiogenesis inhibitor Substances 0.000 description 1
238000010171 animal model Methods 0.000 description 1
238000009534 blood test Methods 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
238000009535 clinical urine test Methods 0.000 description 1
239000002285 corn oil Substances 0.000 description 1
235000005687 corn oil Nutrition 0.000 description 1
239000013078 crystal Substances 0.000 description 1
230000008021 deposition Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
ZKQFHRVKCYFVCN-UHFFFAOYSA-N ethoxyethane;hexane Chemical compound CCOCC.CCCCCC ZKQFHRVKCYFVCN-UHFFFAOYSA-N 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
235000019256 formaldehyde Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
239000003292 glue Substances 0.000 description 1
239000008187 granular material Substances 0.000 description 1
230000009931 harmful effect Effects 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
208000019423 liver disease Diseases 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
210000001161 mammalian embryo Anatomy 0.000 description 1
238000005259 measurement Methods 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
239000011259 mixed solution Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
239000010502 orange oil Substances 0.000 description 1
150000002978 peroxides Chemical class 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
208000005069 pulmonary fibrosis Diseases 0.000 description 1
238000011160 research Methods 0.000 description 1
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
239000000243 solution Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000012360 testing method Methods 0.000 description 1
DGQOCLATAPFASR-UHFFFAOYSA-N tetrahydroxy-1,4-benzoquinone Chemical compound OC1=C(O)C(=O)C(O)=C(O)C1=O DGQOCLATAPFASR-UHFFFAOYSA-N 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
210000004291 uterus Anatomy 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Emergency Medicine (AREA)
Immunology (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Diabetes (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

JP57057474A 1982-04-06 1982-04-06 動物組織の線維化抑制剤 Granted JPS58174313A (ja)

Priority Applications (4)

Application Number	Priority Date	Filing Date	Title
JP57057474A JPS58174313A (ja)	1982-04-06	1982-04-06	動物組織の線維化抑制剤
US06/479,074 US4514420A (en)	1982-04-06	1983-03-25	Antifibrotic agent
DE3311922A DE3311922C2 (de)	1982-04-06	1983-03-31	Verwendung von substituierten 1,4-Benzochinonen bei der Prophylaxe oder Behandlung von Fibrose
IT48031/83A IT1167113B (it)	1982-04-06	1983-03-31	Composizione farmaceutica contenente un composto di 1,4-benzochinone e suo impiego come agente antifibrotico

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP57057474A JPS58174313A (ja)	1982-04-06	1982-04-06	動物組織の線維化抑制剤

Publications (2)

Publication Number	Publication Date
JPS58174313A true JPS58174313A (ja)	1983-10-13
JPH0139405B2 JPH0139405B2 (2)	1989-08-21

Family

ID=13056694

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP57057474A Granted JPS58174313A (ja)	1982-04-06	1982-04-06	動物組織の線維化抑制剤

Country Status (4)

Country	Link
US (1)	US4514420A (2)
JP (1)	JPS58174313A (2)
DE (1)	DE3311922C2 (2)
IT (1)	IT1167113B (2)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0201196B1 (en) *	1985-04-08	1991-07-03	Takeda Chemical Industries, Ltd.	Benzoquinone derivatives, their production and use
WO1987001698A2 (en) *	1985-09-20	1987-03-26	The Upjohn Company	1,4-naphthalenediol and 1,4-hydroquinone derivatives
US4939169A (en) *	1985-09-20	1990-07-03	The Upjohn Company	1,4-naphthalenediol and 1,4-hydroquinone derivatives
EP0301861B1 (en) *	1987-07-29	1992-04-01	Takeda Chemical Industries, Ltd.	Cell proliferation inhibitors
US5789426A (en) *	1995-01-20	1998-08-04	Cornell Research Foundation, Inc.	Method for the treatment of fibroproliferative disorders by application of inhibitors of protein hydroxylation
EP0788793A1 (en)	1996-02-01	1997-08-13	Takeda Chemical Industries, Ltd.	Idebenone for the treatment of dementia
EP0813866A3 (en) *	1996-06-17	1999-01-20	Eisai Co., Ltd.	Therapeutic agent for joint diseases
WO2011139628A1 (en)	2010-04-25	2011-11-10	Mount Sinai School Of Medicine	Generation of anterior foregut endoderm from pluripotent cells
US9988606B2 (en)	2012-07-24	2018-06-05	The Trustees Of Columbia University In The City Of New York	Generation of airway and lung progenitors and epithelial cells and three-dimensional anterior foregut spheres
JP7169580B2 (ja) *	2018-09-27	2022-11-11	株式会社Ｌｔｔバイオファーマ	線維症治療用医薬組成物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5919930B2 (ja) *	1974-05-02	1984-05-09	武田薬品工業株式会社	キノン酸誘導体の製造法
US4271083A (en) *	1974-05-02	1981-06-02	Takeda Chemical Industries, Ltd.	6-Hydroxy-1,4-benzoquinone compounds
JPS54160740A (en) *	1978-06-09	1979-12-19	Takeda Chem Ind Ltd	Anti-fibrotic agent
EP0021841B1 (en) *	1979-06-28	1984-10-24	Takeda Chemical Industries, Ltd.	2,3-dialkoxy-1,4-quinone derivatives; method of producing 1,4-quinone derivatives
JPS5697223A (en) *	1979-12-30	1981-08-05	Takeda Chem Ind Ltd	Tissue metabolism activator
JPS56150014A (en) *	1980-04-21	1981-11-20	Takeda Chem Ind Ltd	Antiallergic agent

1982
- 1982-04-06 JP JP57057474A patent/JPS58174313A/ja active Granted
1983
- 1983-03-25 US US06/479,074 patent/US4514420A/en not_active Expired - Fee Related
- 1983-03-31 IT IT48031/83A patent/IT1167113B/it active
- 1983-03-31 DE DE3311922A patent/DE3311922C2/de not_active Expired - Fee Related

Also Published As

Publication number	Publication date
IT8348031A0 (it)	1983-03-31
JPH0139405B2 (2)	1989-08-21
US4514420A (en)	1985-04-30
IT1167113B (it)	1987-05-13
DE3311922C2 (de)	1994-06-23
DE3311922A1 (de)	1983-10-13

Publication	Publication Date	Title
JP6773915B2 (ja)	2020-10-21	前立腺癌を治療する組み合わせ、薬物組成物および治療方法
US5846962A (en)	1998-12-08	Anti-obesity agents
AU2011230081A1 (en)	2012-09-20	Pharmaceutical composition for the prevention or the treatment of non-alcoholic fatty liver disease and the method for prevention or treatment of non-alcoholic fatty liver disease using the same
EA023435B1 (ru)	2016-06-30	Фармацевтическая композиция, включающая новый холиновый сокристалл эпалрестата
JPH0776174B2 (ja)	1995-08-16	医薬組成物および処置法
WO2021027582A1 (zh)	2021-02-18	包含柠檬苦素类化合物和噻唑烷二酮类药物的组合产品
US4505921A (en)	1985-03-19	Sulfonylurea compounds and their use in treating diabetes
CN106474110B (zh)	2019-10-08	异土木香内酯衍生物及其盐在制备治疗甲状腺炎药物中的应用
JPH02180830A (ja)	1990-07-13	ヘコゲニンのエステル誘導体含有医薬組成物および前立腺肥大症の治療におけるその使用方法
US4514420A (en)	1985-04-30	Antifibrotic agent
JPH1053520A (ja)	1998-02-24	抗疲労剤
EP4119165A1 (en)	2023-01-18	Novel 3,5-diaminobenzoic acid compound, and pin1 inhibitor and therapeutic agent for inflammatory diseases using same
US4851414A (en)	1989-07-25	Anti-dementia agent
BE882315A (fr)	1980-09-19	Composes de 6-aryl pyrimidine, leur preparation et leur utilisation
JPH0560447B2 (2)	1993-09-02
WO1997002822A1 (en)	1997-01-30	Drug for ameliorating brain diseases
US3143469A (en)	1964-08-04	Anti-cholesterol nicotinic acid nu-oxide
CN106496169B (zh)	2019-10-08	土木香内酯衍生物及其盐
US3462534A (en)	1969-08-19	Production of an antidepressant effect with esters of gallic acid
JPS58208231A (ja)	1983-12-03	コレカルシフエロ−ル誘導体含有薬剤
EP4186503A1 (en)	2023-05-31	Anti-inflammatory composition comprising benzofuran-based n-acylhydrazone derivatives
JPS58164507A (ja)	1983-09-29	ジベンゾシクロヘプテニリデン類による免疫変化剤
US2899358A (en)	1959-08-11	Process
US20250205193A1 (en)	2025-06-26	Therapeutic compound and salts
JP2756941B2 (ja)	1998-05-25	２−クロロ−３−アリールアミノ−１，４−ナフトキノン誘導体の血小板凝集抑制剤としての用途